Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
- First Posted Date
- 2009-06-05
- Last Posted Date
- 2012-12-17
- Lead Sponsor
- University Hospital Muenster
- Target Recruit Count
- 214
- Registration Number
- NCT00915252
- Locations
- 🇩🇪
RWTH Aachen, Medizinische Klinik IV, Aachen, Germany
🇩🇪Sozialstiftung Bamberg, Klinikum am Bruderwald, Med. Klinik V, Bamberg, Germany
🇩🇪Klinikum Bayreuth, Medizinische Klinik IV, Bayreuth, Germany
Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: FLAIMy - Fluda, Ida, Ara-C, Mylotarg
- First Posted Date
- 2009-05-27
- Last Posted Date
- 2014-05-06
- Lead Sponsor
- University Hospital, Udine, Italy
- Target Recruit Count
- 130
- Registration Number
- NCT00909168
- Locations
- 🇮🇹
University Hospital, Udine, Udine, Italy
Study Evaluating Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Less Than 60 Years of Age
- First Posted Date
- 2009-05-06
- Last Posted Date
- 2016-02-05
- Lead Sponsor
- Technische Universität Dresden
- Target Recruit Count
- 276
- Registration Number
- NCT00893373
- Locations
- 🇩🇪
Sozialstiftung Bamberg Klinikum am Bruderwald, Bamberg, Germany
🇩🇪Klinikum Bayreuth, Bayreuth, Germany
🇩🇪Charite Campus Benjamin Franklin, Berlin, Germany
Study of Chemotherapy in Combination With All-trans Retinoic Acid (ATRA) With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (AML) and Mutant Nucleophosmin-1 (NPM1) Gene Mutation
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: Gemtuzumab Ozogamicin (Mylotarg)Drug: standard chemotherapy
- First Posted Date
- 2009-05-06
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- University of Ulm
- Target Recruit Count
- 600
- Registration Number
- NCT00893399
- Locations
- 🇦🇹
Medizinische Universitäts Graz, Graz, Austria
🇦🇹Universitätsklinikum Innsbruck, Innsbruck, Austria
🇦🇹Krankenhaus der Barmherzigen Schwestern Linz Betriebsgesellschaft m.b.H., Linz, Austria
Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia (AML)Adult Acute Myeloblastic Leukemia
- Interventions
- First Posted Date
- 2009-04-30
- Last Posted Date
- 2018-06-18
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 45
- Registration Number
- NCT00890929
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q
- Conditions
- Myelodysplastic SyndromeChronic Myelomonocytic LeukemiaAcute Myeloid Leukemia
- Interventions
- First Posted Date
- 2009-04-22
- Last Posted Date
- 2015-04-24
- Lead Sponsor
- Groupe Francophone des Myelodysplasies
- Target Recruit Count
- 85
- Registration Number
- NCT00885508
- Locations
- 🇫🇷
CH Angers, Angers, France
🇫🇷hopital Victor Dupouy, Argenteuil, France
🇫🇷Centre Hospitalier de La Cote Basque, Bayonne, France
Effect of Priming During Induction and Consolidations in Younger Acute Myeloid Leukemia (AML)
- First Posted Date
- 2009-04-13
- Last Posted Date
- 2009-04-13
- Lead Sponsor
- Acute Leukemia French Association
- Target Recruit Count
- 473
- Registration Number
- NCT00880243
Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL)
- Conditions
- ALLBALMDSAML
- First Posted Date
- 2009-03-17
- Last Posted Date
- 2017-07-19
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT00863148
- Locations
- 🇫🇷
Hôpital Edouard Herriot, Lyon, France
🇫🇷Institut Paoli Calmettes, Marseille, France
🇫🇷Nantes University hospital, Nantes, France
Efficacy of Gemtuzumab Ozogamycin for Patients Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: gemtuzumab ozogamycin
- First Posted Date
- 2009-03-12
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 327
- Registration Number
- NCT00860639
- Locations
- 🇫🇷
CH Pays d'Aix, Aix, France
🇫🇷CHU Amiens, Amiens, France
🇫🇷CHRU Angers, Angers, France
Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2009-02-25
- Last Posted Date
- 2016-03-01
- Lead Sponsor
- University of Ulm
- Target Recruit Count
- 89
- Registration Number
- NCT00850382
- Locations
- 🇦🇹
Universitätsklinikum Innsbruck, Innsbruck, Austria
🇦🇹Krankenhaus der Barmherzigen Schwestern, Linz, Austria
🇦🇹Elisabethinen Krankenhaus, Linz, Austria